Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease (MOIPAD)

Peking University

Status: Enrolling

Conditions: Alzheimer's Disease (AD)

Treatments: Diagnostic Test: Multimodal Ophthalmic Imaging and plasma biomarker

Study type: Observational

Funder types: Other

Identifiers

NCT06924359

AD-BIOPR-001

Details and patient eligibility

About

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Enrollment: 200 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female participants aged ≥ 50 years;
• Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);
• Signed informed consent form

Exclusion criteria

• Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;
• Inability to cooperate with cognitive assessments;
• Refusal to undergo blood sampling.

Trial design

200 participants in 1 patient group

Different stages of Alzheimer's disease

Treatment:

Diagnostic Test: Multimodal Ophthalmic Imaging and plasma biomarker